Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal

Executive Summary

LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.


Related Content

Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role
Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth
Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules
Five Reasons Why GSK Spinning Off Consumer Is Not So Straightforward
Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals
Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
J&J/Janssen win OK for Sylvant; 1st US drug in Castleman's


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts